The health care market is failing to support new antibiotics used to treat some of the world’s most dangerous, drug-resistant ‘superbugs,’ according to a new analysis.
The health care market is failing to support new antibiotics used to treat some of the world’s most dangerous, drug-resistant ‘superbugs,’ according to a new analysis.